ESTRO 2025 - Abstract Book

S1170

Clinical – Lower GI

ESTRO 2025

(PUMC), Shenzhen, China. 3 Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China. 4 Department of Radiation Oncology, Peking University Cancer Hospital and Institute, Beijing, China. 5 Department of Radiation Oncology, Xijing Hospital, Air Force Medical University, Xi’an, China. 6 Department of Radiation Oncology, Jilin Provincial Cancer Hospital, Changchun, China. 7 Department of Oncology, Affiliated Hospital of Guizhou Medical University, Guiyang, China Purpose/Objective: Total neoadjuvant therapy is further accepted for the treatment of locally advanced rectal cancer, which is more valuable for patients with high-risk factors. Optimal schedule of radiotherapy and chemotherapy remains unknow and needs further exploration. Material/Methods: We conducted a multicenter, randomized, phase II trial (ClinicalTrials.gov No.: NCT04543695). Patients aged 18-75 years with initial stage II / III rectal adenocarcinoma ( At least one of high-risk factors should be included: mesorectal fascia involvement, T4, N2, positive lateral lymph node, or extramural vessel invasion) were assigned into three groups, 1) Chemoradiotherapy (50 Gy of radiation combined with oral capecitabine) followed by consolidation chemotherapy using six cycles of XELOX (CNCT group) , 2) Induction chemotherapy before chemoradiotherapy (INCT group) , or 3) Chemoradiotherapy alone (Control group) . Then enrolled patients were required to undergo radical surgery after neoadjuvant therapy. Patients in Control group need six cycles of XELOX after surgery. The primary end point was proportion of yp0-II, and watch-and-wait strategy after complete clinical response (cCR) was allowed. Results: Of the 257 patients enrolled, 255 patients were evaluable (Control: CNCT: INCT= 84: 86: 85). Neoadjuvant treatment related grade 3 or 4 toxicity was higher in TNT approach (7.1%, 23.3% and 32.9% in Control, CNCT and INCT, respectively), of with myelosuppression being most common. Compliance of chemoradiotherapy was lower in INCT group (98.8%, 100% and 90.6% in Control, CNCT and INCT, respectively). As to CNCT and INCT, 60.0% and 74.1% of patients completed six cycles of chemotherapy, with 76.7% and 83.5% completing four cycles of chemotherapy, respectively. Proportions of downstage (yp0-II + sustained cCR) were achieved 75.6% in CNCT group and 74.1% in INCT group, respectively, compared to 56.0% in Control group. CR rates (pCR + sustained cCR) were achieved 43.0% in CNCT group and 38.8% in INCT group, respectively, compared to 20.2% in Control group. Both TNT approaches did not increase the incidence of surgical complications (6.0%, 8.1% and 10.9% in Control, CNCT and INCT, respectively), with anastomotic fistula and abdominal infection being of most common. Conclusion: Both TNT approaches increased the probability of ≥ G3 acute toxicities, but most patients could tolerate 4 cycles of neoadjuvant chemotherapy. Both TNT approaches could achieve a higher proportion of downstage and CR rate.

Keywords: rectal cancer ， totally neoadjuvant therapy

1489

Proffered Paper STAR-TREC (NCT02945566): A randomised phase II/III trial of CRT versus 5x5 Gy SCRT for organ preservation in early/intermediate risk rectal cancer Corrie AM Marijnen 1,2 , David Sebag-Montefiore 3 , Victoria Homer 4 , Simon Gates 4 , Issam Al-Najami 5 , Eva Angenete 6,7 , Ane Appelt 3 , Gunnar Baatrup 5,8 , Geerard Beets 9,10 , Jacobus WA Burger 11 , Karen-Lise Garm Spindler 12,13 , Ian Geh 14 , Alexandra Gilbert 3 , Karin Haustermans 15 , Fabian Holman 16 , Stephan Korsgen 17 , Pehr Lind 18 , Anna Martling 19,20 , Femke Peters 1 , Mark Teo 21 , Nicholas West 22 , Albert Wolthuis 23 , Johannes WH de Wilt 24 , Simon P Bach 25